Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A

Inclusion Criteria: * 12 to 65 years old; * The activity of the coagulation factor VIII (FVIII:C) ≤5%, and was previously treated with FVIII concentrate(s) for a minimum of 50 exposure days (EDs) prior to study entry * Bleeding state need to be treated with FVIII; * Negative assays for FVIII inhibitors (\<0.6 BU/mL); * The platelet count is normal； * Normal prothrombin time or INR ≤1.5； * Given informed consent Exclusion Criteria: * Hypersensitivity to recombinant coagulation factor VIII concentrate or any of the excipients ;allergic to heterologous proteins (e.g. murine, bovine or hamster origin); * Family history or history of FVIII inhibitors (≥0.6 Bethesda Units \[BU\] mL-1); * Received an infusion of any FVIII for on-demand therapy or prophylaxis within 4 days prior to study entry (including rFVIII, plasma-derived factor VIII \[pdFVIII\], cryoprecipitate and whole blood); * Significant hepatic or renal impairment (ALT and AST ≥2×ULN; BUN and Cr≥2×ULN); * HIV seropositive; * Abnormal hemostasis from causes other than hemophilia A； * Patients with severe heart disease, including myocardial infarction, heart failure (III or higher level); * Patients who received any anticoagulant or antiplatelet therapy within one week (including NSAIDs) or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials; * Alcoholism, drug abuse, mental disorders and mental retardation; * Elective surgery planned during the process of study; * Patients who previously participated in the other clinical trials prior to study entry; * The patient or parent/legal guardian is unable or unwilling to sign an informed consent form or to comply with the requirements of clinical protocol; * Other conditions confirmed by the researchers, resulting in that patients are unable to benefit from clinical observation;